

2021 Virtual Conference

Closing Remarks



John DiBella
President, Simulations Plus Division



Jonathan Chauvin President, Lixoft



MIDD+ 2021 Conference Evolution:

Evolving relationship between M&S and pharma R&D

- Model "supported" (questions 20 years ago):
 - Do you think modeling and simulation might help?
- Model "based" (questions 5 years ago):
 - How can I maximize the value of modeling and simulation in my development program?
- Model "informed" (questions today):
 - How do I change the entire R&D process to reflect the availability of M&S tools and techniques?



MIDD+ 2021 Highlights

Jonathan

- MIDD in its overall, from discovery to post approval
- The role of education
- "The more we know, the more we understand that there is still a lot to understand"

John

- Information rich presentations from health authorities
- Women in Science & Leadership!
- "All that glitters is not gold..."







MIDD+ 2021 Acknowledgements







MIDD+ 2022... What's to Come

- Applications of precision dosing
- Machine learning and QST
- Next-generation platforms
- Other ideas?





Stay Tuned... Spring Events @ Simulations Plus



- Next week ASCPT 2021!
- April 21st @ 8:00 AM PDT

Early assessment of PK properties with the ADMET Predictor® HTPK Simulation module, a high-throughput mechanistic PBPK approach

Dr. Andrés Olivares

Project Leader, DMPK/PD, Modeling and Simulation and Clinical Pharmacology at Roche, Basel

For the latest news & events, visit:

Model-Informed Drug Development

2021 Virtual Conference

<u>www.simulations-plus.com</u>



Model-Informed Drug Development

2021 Virtual Conference

Thank you for attending!

